FK506 in the treatment of inflammatory skin disease: Promises and perspectives

Günter Michel, Lajos Kemény, Bernhard Homey, Thomas Ruzicka

Research output: Comment/debate

40 Citations (Scopus)

Abstract

The immunosuppressive macrolide drug FK506 is currently gaining increasing importance in dermatopharmacology. Here, Gunter Michel and colleagues summarize the current state of research into the molecular mechanisms responsible for the functional modulation of cell types other than T cells, particularly epidermal cells, by this drug.

Original languageEnglish
Pages (from-to)106-108
Number of pages3
JournalImmunology today
Volume17
Issue number3
DOIs
Publication statusPublished - márc. 1996

    Fingerprint

ASJC Scopus subject areas

  • Immunology

Cite this